MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer - 10/06/22
, Astrid Lièvre a, ab, ⁎, 1 Highlights |
• | miR-31-3p expression is predictive of anti-EGFR efficacy in mCRC. |
• | Primary tumor side is prognostic and predictive of anti-EGFR efficacy in mCRC. |
• | In right-sided RAS-wt mCRC, miR-31-3p expression do not predict anti-EGFR efficacy and bevacizumab is the targeted therapy of choice whatever miR-31-3p expression level. |
Abstract |
Background |
Low miR-31-3p expression was identified as predictive of anti-EGFR efficacy in RAS-wt mCRC. Primary tumor side was also proposed as a predictive factor of anti-EGFR benefit. This retrospective multicentric study evaluated the predictive role of miR-31-3p in right-sided RAS-wt mCRC patients treated with first-line CT+anti-EGFR or CT+bevacizumab (Beva).
Methods |
Seventy-two right-sided RAS-wt mCRC patients treated in first-line with CT+anti-EGFR (n = 43) or Beva (n = 29) were included. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were analyzed and stratified according to tumor miR-31-3p expression level and targeted therapy (TT).
Results |
BRAF V600E mutation was more frequent in high vs low miR-31-3p expressers (60.6% vs 15.4%, P < 0.001). PFS was significantly longer with CT+Beva than with CT+anti-EGFR (13 vs 7 months; P = 0.024). Among low miR-31-3p expressers, PFS, OS and RR were not significantly different between the two groups, while in high miR-31-3p expressers, only PFS was longer in the CT+Beva group (11 vs 6 months; P = 0.03). In patients treated with CT+anti-EGFR, low miR-31-3p expressers had a significantly longer OS (20 vs 13 months; P = 0.02) than high miR-31-3p expressers. ORR was not significantly different between the two groups of treatment, in both low and high miR-31-3p expressers. MiR-31-3p expression status was statistically correlated between primary tumors and corresponding metastases.
Conclusion |
In this study, miR-31-3p couldn't identify a subgroup of patients with right-sided RAS-wt mCRC who might benefit from anti-EGFR and suggest that Beva is the TT of choice in first-line treatment of these patients.
Le texte complet de cet article est disponible en PDF.Keywords : Colorectal cancer, Metastasis, Biomarker, miR-31-3p, anti-EGFR mAb, Bevacizumab
Plan
Vol 46 - N° 5
Article 101888- mai 2022 Retour au numéro
Article précédent
- The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience
- Anna Boulouta, Ioanna Aggeletopoulou, Stavros Kanaloupitis, Efthymios P Tsounis, Vasileios Issaris, Konstantinos Papantoniou, Anastasios Apostolos, Paraskevas Tsaplaris, Ploutarchos Pastras, Christos Sotiropoulos, Aggeliki Tsintoni, Georgia Diamantopoulou, Konstantinos Thomopoulos, Marina Michalaki, Christos Triantos
- Fecal incontinence subtype assessment (FI-SA): A new tool to distinguish among subtypes of fecal incontinence in a neurogenic population
- C. Desprez, N. Turmel, C. Chesnel, S. Sheikh Ismael, M. Tamiatto, E. Tan, R. Haddad, F. Le Breton, A.-M. Leroi, C. Hentzen, G. Amarenco
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?